This prospective study aimed to explore, in a multifaceted approach, potential predictive biomarkers of response to anti-TNF therapy and vedolizumab in ulcerative colitis (UC) and Crohn’s disease (CD), using pCLE, fluorescein isothiocyanate labeling, immunohistochemistry, and gene expression analysis. This evidence concerns the gene TNF and ulcerative colitis.